Experience of Using Delamanid in the Treatment of Multiple Drug Resistant Tuberculosis
https://doi.org/10.58838/2075-1230-2024-102-4-78-82
Abstract
The objective: to evaluate treatment results in MDR TB patients when delamanid is added to the treatment regimen.
Subjects and Methods. 91 patients with multiple drug resistant pulmonary tuberculosis were included in the study, of which 36 people (39.6%) were HIV positive. Patients were divided into four comparison groups depending on HIV status and inclusion of delamanid in the treatment regimen. Groups receiving delamanid included only patients in whom bedaquiline or linezolid had been discontinued due to adverse reactions.
Results. The results of treatment of MDR TB when delamanid is added to the chemotherapy regimen during the intensive phase, indicate its high effectiveness and safety including HIV positive patients.
About the Authors
T. R. Bagdasaryan
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Tatevik R. Bagdasaryan, Candidate of Medical Sciences, Head of Clinic no. 1, Associate Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
M. A. Plekhanova
Moscow Regional Clinical TB Dispensary; M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Maria A. Plekhanova, Doctor of Medical Sciences, Deputy Head Physician for Research, Professor of Phthisiology Department
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
V. Yu. Smirnov
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Vyacheslav Yu. Smirnov, Deputy Head of Sukmanikha Hospital
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
E. A. Grigorieva
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Elena A. Grigorieva, Candidate of Medical Sciences, Head of Department of Clinic no. 1
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
Yu. I. Timakova
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Yulia I. Timakova, Deputy Head of Medical Department, Clinic no. 1
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
A. S. Goncharov
Moscow Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Andrey S. Goncharov, Head of Sukmanikha Hospital
11 Bd. 1 Borby Sq., Moscow, 127030
Phone: +7 (496) 588-41-29
References
1. Zimina V.N., Viktorova I.B. Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects. Tuberculosis and Lung Diseases, 2021, vol. 99, no. 2, pp. 58-66. (In Russ.)
2. Maryandyshev A.O., Lorsanov S.M., Khaydarkhanova Z.B., Khunkarsultanov S.B., Perkhin D.V., Sveshnikova O.M., Gayda A.I., Privolnev V.V. Treatment outcomes of regimens containing delamanid within therapy of multiple and extensive drug resistant tuberculosis in the Russian Federation. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 11, pp. 67-68. (In Russ.)
3. Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Abramchenko A.V. Delamanid: safety and efficacy analysis Tuberculosis and Lung Diseases, 2023, vol. 101, no. 6, pp. 102-110. (In Russ.) https://doi.org/10.58838/2075-1230-2023-101-6-102-110
4. Nechaeva O.B. TB situation in Russia. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 8, pp. 15-24. (In Russ.)
5. Otraslevye i ekonomicheskie pokazateli protivotuberkuleznoy raboty v 2017-2018 gg. Analiticheskiy obzor osnovnykh pokazateley i statisticheskiye materialy. [Sectoral and economic rates for TB control in 2017-2018. Analysis of main rates and statistic materials]. Moscow, RIO TSNIIOIZ Publ., 2019,
6. Federal Service of State Statistics. Available: http:www.gks.ru. Accessed May 12, 2018
7. Barry P.J., O’Connor T.M. Novel agents in the management of Mycobacterium tuberculosis disease. Curr. Med. Chem., 2007, no. 14, pp. 2000-2008.
8. Deltyba EPAR Product Information, Annex I, Summary of product characteristics. European Medicines Agency, Committee for Medicinal Products for Human Use. 2014. Available: https://www.ema.europa.eu/en/documents/product-information/deltyba-epar-product-information_en.pdf Accessed October 03, 2023
9. Deltyba, INN-Delamanid-European Medicines Agency-Europa. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba Accessed October 01, 2023
10. Gler M.T., Skripconoka V., Sanchez-Garavito E., Xiao H., Cabrera-Rivero J.L., Vargas-Vasquez D.E. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2012, no. 366, pp. 2151-2160.
11. Global tuberculosis report 2023. Geneva, World Health Organization, 2023. Licence: CC BY-NC-SA 3.0 IGO. Available: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosisreport-2023 Accessed October 5, 2023
12. Matsumoto M., Hashizume H., Tomishige T. et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLos Med., 2006, vol. 11, no. 3, pp. e466.
13. Mohr E., Hughes J., Reuter A., Trivino Duran L., Ferlazzo G., Daniels J. et al. Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. Eur. Respir. J., 2018, vol. 51, no. 6, pp. 1800017.
Review
For citations:
Bagdasaryan T.R., Plekhanova M.A., Smirnov V.Yu., Grigorieva E.A., Timakova Yu.I., Goncharov A.S. Experience of Using Delamanid in the Treatment of Multiple Drug Resistant Tuberculosis. Tuberculosis and Lung Diseases. 2024;102(4):78-82. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-4-78-82
Views:
220
Email this article 